Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Pharmacological treatment of Parkinson disease: a review.

Connolly BS, Lang AE.

JAMA. 2014 Apr 23-30;311(16):1670-83. doi: 10.1001/jama.2014.3654. Review.

PMID:
24756517
2.

Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.

Stowe R, Ives N, Clarke CE, Deane K; van Hilten, Wheatley K, Gray R, Handley K, Furmston A.

Cochrane Database Syst Rev. 2010 Jul 7;(7):CD007166. doi: 10.1002/14651858.CD007166.pub2. Review.

PMID:
20614454
3.

Current and experimental treatments of Parkinson disease: A guide for neuroscientists.

Oertel W, Schulz JB.

J Neurochem. 2016 Oct;139 Suppl 1:325-337. doi: 10.1111/jnc.13750. Epub 2016 Aug 30. Review.

4.

Rationale for current therapies in Parkinson's disease.

Romrell J, Fernandez HH, Okun MS.

Expert Opin Pharmacother. 2003 Oct;4(10):1747-61. Review.

PMID:
14521485
5.

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.

Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C.

Mov Disord. 2011 Oct;26 Suppl 3:S42-80. doi: 10.1002/mds.23884. Review.

6.

Non-dopaminergic treatments for motor control in Parkinson's disease.

Fox SH.

Drugs. 2013 Sep;73(13):1405-15. doi: 10.1007/s40265-013-0105-4. Review. Erratum in: Drugs. 2014 Jul;74(11):1305.

PMID:
23917951
7.

Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.

Faulkner MA.

Expert Opin Drug Saf. 2014 Aug;13(8):1055-69. doi: 10.1517/14740338.2014.931369. Epub 2014 Jun 24. Review.

PMID:
24962891
8.

Current strategies in the treatment of Parkinson's disease and a personalized approach to management.

Diaz NL, Waters CH.

Expert Rev Neurother. 2009 Dec;9(12):1781-9. doi: 10.1586/ern.09.117. Review.

PMID:
19951137
9.

Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.

Pahwa R.

J Am Med Dir Assoc. 2006 Sep;7(7 Suppl 2):4-10. Review.

PMID:
17948613
10.

Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.

Deane KH, Spieker S, Clarke CE.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004553. Review.

PMID:
15495118
11.

Recent developments in the pharmacological treatment of Parkinson's disease.

Tuite P, Riss J.

Expert Opin Investig Drugs. 2003 Aug;12(8):1335-52. Review.

PMID:
12882620
12.
13.

Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.

Tse W.

J Am Med Dir Assoc. 2006 Sep;7(7 Suppl 2):12-7. Review.

PMID:
17948614
14.

Emerging drugs for Parkinson's disease.

Morgan JC, Sethi KD.

Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17. Review.

PMID:
16939381
15.

Parkinson's disease: medical treatment of moderate to advanced disease.

Suchowersky O.

Curr Neurol Neurosci Rep. 2002 Jul;2(4):310-6. Review.

PMID:
12044250
16.

Parkinson disease: managing a complex, progressive disease at all stages.

Giroux ML.

Cleve Clin J Med. 2007 May;74(5):313-4, 317-8, 320-2 passim. Review.

PMID:
17506237
17.

Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.

Stacy M, Galbreath A.

Clin Neuropharmacol. 2008 Jan-Feb;31(1):51-6. doi: 10.1097/WNF.0b013e318065b088. Review.

PMID:
18303491
18.

Levodopa-related wearing-off in Parkinson's disease: identification and management.

Pahwa R, Lyons KE.

Curr Med Res Opin. 2009 Apr;25(4):841-9. doi: 10.1185/03007990902779319 . Review.

PMID:
19228103
19.

Parkinson's disease: diagnosis and treatment.

Rao SS, Hofmann LA, Shakil A.

Am Fam Physician. 2006 Dec 15;74(12):2046-54. Review.

20.

Treatment of levodopa-induced motor complications.

Stocchi F, Tagliati M, Olanow CW.

Mov Disord. 2008;23 Suppl 3:S599-612. doi: 10.1002/mds.22052. Review.

PMID:
18781681

Supplemental Content

Support Center